Eli Lilly looks beyond its blockbuster obesity drugs with another smart deal
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Eli
since
auto-detected in 512 stories
6 days ago
Eli Lilly strikes $1.3 billion deal to buy gene-editing startup Verve Therapeutics, companies say
Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its weight-loss and diabetes drugs.
27 days ago
Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday.
35 days ago
Israel recovers archive belonging to spy Eli Cohen, hanged in Syria in 1965
found
Eli Cohen, who was born in Egypt, is one of Israeli most famous ever operatives. He is widely credited with helping Israel to prepare for the Six-Day War.
46 days ago
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
found
a story from The Economist ✅ › Business
Despite a late start, the American firm is bearing down on its Danish rival
52 days ago
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.
Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
Ricks said reshoring manufacturing capacity for older essential medicines is "a valid thing," adding that Eli Lilly is "happy to help."
61 days ago
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.
67 days ago
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.